title: Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients.
abstract: Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation.We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant.Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.
authors.affiliation: Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University of Rome, Rome, Italy.
authors.forename: Saveria
authors.initials: S
authors.lastname: Capria
authors.forename: Silvia Maria
authors.initials: SM
authors.lastname: Trisolini
authors.forename: Clara
authors.initials: C
authors.lastname: Minotti
authors.forename: Caterina
authors.initials: C
authors.lastname: Stefanizzi
authors.forename: Luisa
authors.initials: L
authors.lastname: Cardarelli
authors.forename: Claudio
authors.initials: C
authors.lastname: Cartoni
authors.forename: Daniela
authors.initials: D
authors.lastname: Diverio
authors.forename: Maria Stefania
authors.initials: MS
authors.lastname: De Propris
authors.forename: Marco
authors.initials: M
authors.lastname: Mancini
authors.forename: Alessandra
authors.initials: A
authors.lastname: Micozzi
authors.forename: Robin
authors.initials: R
authors.lastname: Foà
authors.forename: Giovanna
authors.initials: G
authors.lastname: Meloni